Integer Competitors

Integer (NYSE:ITGR) and Abbott Laboratories (NYSE:ABT) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability and risk.

Risk & Volatility

Integer has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500.

Earnings and Valuation

This table compares Integer and Abbott Laboratories' gross revenue, earnings per share and valuation.

Abbott Laboratories has higher revenue and earnings than Integer. Integer is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Integer and Abbott Laboratories, as provided by MarketBeat.

Integer currently has a consensus price target of $99.3333, indicating a potential upside of 27.11%. Abbott Laboratories has a consensus price target of $115.6875, indicating a potential upside of 0.84%. Given Integer's higher possible upside, analysts plainly believe Integer is more favorable than Abbott Laboratories.

Institutional and Insider Ownership

96.5% of Integer shares are held by institutional investors. Comparatively, 72.6% of Abbott Laboratories shares are held by institutional investors. 2.2% of Integer shares are held by insiders. Comparatively, 1.7% of Abbott Laboratories shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Integer and Abbott Laboratories' net margins, return on equity and return on assets.

Summary

Abbott Laboratories beats Integer on 8 of the 13 factors compared between the two stocks.

Integer (NYSE:ITGR) and Medtronic (NYSE:MDT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk and valuation.

Volatility & Risk

Integer has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500.

Valuation and Earnings

This table compares Integer and Medtronic's gross revenue, earnings per share and valuation.

Medtronic has higher revenue and earnings than Integer. Integer is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Integer and Medtronic, as provided by MarketBeat.com.

Integer currently has a consensus price target of $99.3333, indicating a potential upside of 27.11%. Medtronic has a consensus price target of $122.2963, indicating a potential upside of 4.62%. Given Integer's higher possible upside, equities research analysts clearly believe Integer is more favorable than Medtronic.

Institutional & Insider Ownership

96.5% of Integer shares are held by institutional investors. Comparatively, 79.2% of Medtronic shares are held by institutional investors. 2.2% of Integer shares are held by company insiders. Comparatively, 0.5% of Medtronic shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Integer and Medtronic's net margins, return on equity and return on assets.

Summary

Medtronic beats Integer on 10 of the 15 factors compared between the two stocks.

Integer (NYSE:ITGR) and Stryker (NYSE:SYK) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk and valuation.

Institutional & Insider Ownership

96.5% of Integer shares are held by institutional investors. Comparatively, 71.5% of Stryker shares are held by institutional investors. 2.2% of Integer shares are held by company insiders. Comparatively, 6.8% of Stryker shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for Integer and Stryker, as provided by MarketBeat.com.

Integer currently has a consensus price target of $99.3333, indicating a potential upside of 27.11%. Stryker has a consensus price target of $227.4783, indicating a potential downside of 5.04%. Given Integer's stronger consensus rating and higher possible upside, equities research analysts clearly believe Integer is more favorable than Stryker.

Volatility & Risk

Integer has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500. Comparatively, Stryker has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500.

Profitability

This table compares Integer and Stryker's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Integer and Stryker's gross revenue, earnings per share and valuation.

Stryker has higher revenue and earnings than Integer. Integer is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Summary

Stryker beats Integer on 11 of the 15 factors compared between the two stocks.

Intuitive Surgical (NASDAQ:ISRG) and Integer (NYSE:ITGR) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, analyst recommendations, valuation and risk.

Institutional & Insider Ownership

86.5% of Intuitive Surgical shares are owned by institutional investors. Comparatively, 96.5% of Integer shares are owned by institutional investors. 1.6% of Intuitive Surgical shares are owned by insiders. Comparatively, 2.2% of Integer shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Intuitive Surgical and Integer, as reported by MarketBeat.

Intuitive Surgical presently has a consensus target price of $736.0588, indicating a potential downside of 2.12%. Integer has a consensus target price of $99.3333, indicating a potential upside of 27.11%. Given Integer's stronger consensus rating and higher possible upside, analysts clearly believe Integer is more favorable than Intuitive Surgical.

Risk & Volatility

Intuitive Surgical has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500. Comparatively, Integer has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500.

Profitability

This table compares Intuitive Surgical and Integer's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Intuitive Surgical and Integer's revenue, earnings per share (EPS) and valuation.

Intuitive Surgical has higher revenue and earnings than Integer. Integer is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Summary

Intuitive Surgical beats Integer on 9 of the 14 factors compared between the two stocks.

Becton, Dickinson and (NYSE:BDX) and Integer (NYSE:ITGR) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, analyst recommendations, valuation and risk.

Institutional & Insider Ownership

83.2% of Becton, Dickinson and shares are owned by institutional investors. Comparatively, 96.5% of Integer shares are owned by institutional investors. 0.8% of Becton, Dickinson and shares are owned by insiders. Comparatively, 2.2% of Integer shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Becton, Dickinson and and Integer, as reported by MarketBeat.

Becton, Dickinson and presently has a consensus target price of $279.6667, indicating a potential upside of 7.46%. Integer has a consensus target price of $99.3333, indicating a potential upside of 27.11%. Given Integer's stronger consensus rating and higher possible upside, analysts clearly believe Integer is more favorable than Becton, Dickinson and.

Risk & Volatility

Becton, Dickinson and has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Integer has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500.

Profitability

This table compares Becton, Dickinson and and Integer's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Becton, Dickinson and and Integer's revenue, earnings per share (EPS) and valuation.

Becton, Dickinson and has higher revenue and earnings than Integer. Integer is trading at a lower price-to-earnings ratio than Becton, Dickinson and, indicating that it is currently the more affordable of the two stocks.

Summary

Becton, Dickinson and beats Integer on 8 of the 14 factors compared between the two stocks.

Edwards Lifesciences (NYSE:EW) and Integer (NYSE:ITGR) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, analyst recommendations, valuation and risk.

Institutional & Insider Ownership

80.9% of Edwards Lifesciences shares are owned by institutional investors. Comparatively, 96.5% of Integer shares are owned by institutional investors. 1.5% of Edwards Lifesciences shares are owned by insiders. Comparatively, 2.2% of Integer shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Edwards Lifesciences and Integer, as reported by MarketBeat.

Edwards Lifesciences presently has a consensus target price of $90.8704, indicating a potential upside of 5.80%. Integer has a consensus target price of $99.3333, indicating a potential upside of 27.11%. Given Integer's stronger consensus rating and higher possible upside, analysts clearly believe Integer is more favorable than Edwards Lifesciences.

Risk & Volatility

Edwards Lifesciences has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Comparatively, Integer has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500.

Profitability

This table compares Edwards Lifesciences and Integer's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Edwards Lifesciences and Integer's revenue, earnings per share (EPS) and valuation.

Edwards Lifesciences has higher revenue and earnings than Integer. Integer is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Summary

Edwards Lifesciences beats Integer on 8 of the 14 factors compared between the two stocks.